Cargando…

Management of chronic myelogenous leukemia with COVID-19 and hepatitis B

The application of immunosuppressive agents and targeted drugs has opened a novel approach for the treatment of hematological tumors, and the application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia is one of the landmark breakthroughs that has considerably improved th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Tian, Li, Weiming, Yu, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438954/ https://www.ncbi.nlm.nih.gov/pubmed/37601670 http://dx.doi.org/10.3389/fonc.2023.1217023

Ejemplares similares

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia
por: Krishna Chandran, Ramachandran, et al.
Publicado: (2019)

Renal Bleeding Due to Extramedullary Hematopoiesis in a Patient With Chronic Myelogenous Leukemia()
por: Zettner, Stephanie, et al.
Publicado: (2014)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation
por: Liesveld, Jane
Publicado: (2012)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2021)

Bowel Perforation Secondary to Ponatinib Treatment in a Chronic Myelogenous Leukemia Patient: A Case Report
por: Sallam, Asma, et al.
Publicado: (2021)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia
por: Wang, Yun, et al.
Publicado: (2020)

Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells
por: Chen, Zhiwei, et al.
Publicado: (2021)

Integrative Analysis of Multi-Omics Identified the Prognostic Biomarkers in Acute Myelogenous Leukemia
por: Zheng, Jiafeng, et al.
Publicado: (2020)

COVID-19 pneumonia concurrent with newly diagnosed chronic myelogenous leukemia
por: Kim, Chul Soo, et al.
Publicado: (2022)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

Unusual T-Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia
por: Xu, Jie, et al.
Publicado: (2014)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
por: Sobash, Philip T., et al.
Publicado: (2020)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Primary hyperparathyroidism in a case of chronic myelogenous leukemia
por: Valizadeh, Nasim, et al.
Publicado: (2013)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021)

Case Report: Surgical Management in Acute Subdural Hematoma Induced by Chronic Myelogenous Leukemia
por: Moshref, Rana H., et al.
Publicado: (2021)

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
por: Cheng, Fang, et al.
Publicado: (2023)

Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR
por: Wang, Yu Jia, et al.
Publicado: (2017)

Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
por: Kim, Peter S., et al.
Publicado: (2008)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation()
por: Tsukamoto, Shokichi, et al.
Publicado: (2013)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Chronic Myelogenous Leukemia Presenting with Facial Nerve Palsy in an Infant
por: KHAJEH, Ali, et al.
Publicado: (2018)

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
por: Keramatinia, Aliasghar, et al.
Publicado: (2017)

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells
por: Naka, Kazuhito
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_flhh3oihsrqvf8ltg6d5iuqckm